Skip to main content

Type 1 Diabetes Grand Challenge launches first research call

We are delighted to announce that we have opened our first funding round, calling scientists to submit research proposals that could be transformational for people with type 1 diabetes.
23 June 2022

Steve and Sally Morgan in a JDRF-funded lab

Following the exciting announcement in April about a new partnership between the Steve Morgan Foundation, Diabetes UK and JDRF to invest £50m into game-changing type 1 diabetes research, we have opened our first funding round, calling scientists to submit research proposals that could be transformational for people with type 1 diabetes.

First-class research cannot happen without first class researchers. Diabetes UK and JDRF are committed to nurturing the diabetes research leaders of the future, so for the first research call we have worked together to develop a new senior fellowship programme.

Supporting the best research minds

Fellowships are awards for individual researchers that support them to develop their careers, build their own research teams, and make diabetes research their life’s work.

The new Type 1 Diabetes Senior Research Fellowship will allow exceptional researchers, with a track-record of impactful research, to become world leaders in their field and lead the race for new treatments and a cure for type 1 diabetes.

The fellowship will award scientists up to £1.5 million to research:

These areas, along with novel insulins, were identified as carrying the most potential to improve the lives of people with type 1 diabetes and propel us towards a cure.

Rachel Connor, Director of Research Partnerships at JDRF, said:

“We believe in the power of research to one day lift the burden of living with type 1 diabetes, and alongside our partners in the Type 1 Diabetes Grand Challenge we are proud to launch this Senior Fellowship to enable researchers to pursue new ideas to transform lives for people with type 1 diabetes.

We can’t wait to see how this opportunity will deliver in supporting the cutting edge research that the Type 1 Diabetes Grand Challenge has set out to inspire.”

The research community will have until September 2022 to shape their ideas and apply for the fellowship. Diabetes UK and JDRF will then work with research experts and people living with or affected by type 1 diabetes to review the applications. They will select those submitted by researchers with exceptional track-records and that involve the highest quality science, with the greatest chance of benefiting people with type 1 diabetes. We expect to announce the final funding decisions in early 2023 and will keep you updated.

This fellowship will be administered by Diabetes UK on behalf of the Type 1 Diabetes Grand Challenge Partnership.

If you’re a diabetes researcher, find out more information about the call and application process.

Related news

Read more
Nina Willer, who used hybrid closed loop technology through pregnancy, and her child.
Treatment research
7 November 2023

Hybrid closed loop technology set to be made available in England and Wales

The announcement is the biggest treatment breakthrough for type 1 diabetes since the discovery of insulin.

Read more
T cell immune system
6 November 2023

New research highlights the effectiveness of immune therapies for type 1 diabetes

The research, which was co-funded by JDRF, reveals that drugs that target the immune system offer very effective and rapid improvements in stabilising blood sugar levels, often within just three months.

Read more
Dr Ify Mordi, lead type 1 diabetes researcher
Clinical trials
25 October 2023

JDRF award £1.5 million grant to University of Dundee for type 1 diabetes clinical trial

The new JDRF-funded clinical trial called SOPHIST will test a drug to help people with type 1 diabetes and heart failure.

Read more
Young person receiving an injection of the immunotherapy drug teplizumab.jpg
18 October 2023

Clinical trial finds teplizumab slows type 1 diabetes in people newly diagnosed 

Results from a clinical trial called the PROTECT study show that teplizumab can preserve beta cell function in children and adolescents newly diagnosed with type 1 diabetes.